Roche/Genentech to file NDA in 2015

Back in May 14, 2015, Roche announced its plans to file a new drug application for Alectinib in 2015.

http://www.roche.com/media/store/releases/med-cor-2015-05-14.htm

According to several postings on Inspire.com by patients, Alectinib approval by the FDA is expected by the end of October.

https://www.inspire.com/groups/american-lung-association-lung-cancer-survivors/discussion/anyone-on-pf-02341066-crizotinib-alk-gene-part-3/?reply_sort=desc

 

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, Lung cancer, Potential Treatments, Regulatory applications & approvals. Bookmark the permalink.

Leave a Reply